Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy.

Autor: Patin EC; Targeted Therapy Team, The Institute of Cancer Research, London, UK. emmanuel.patin@icr.ac.uk., Nenclares P; Targeted Therapy Team, The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK., Chan Wah Hak C; Targeted Therapy Team, The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK., Dillon MT; Targeted Therapy Team, The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK., Patrikeev A; Targeted Therapy Team, The Institute of Cancer Research, London, UK., McLaughlin M; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Grove L; Targeted Therapy Team, The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK., Foo S; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Soliman H; The Royal Marsden Hospital, London, UK., Barata JP; The Royal Marsden Hospital, London, UK., Marsden J; The Royal Marsden Hospital, London, UK., Baldock H; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Gkantalis J; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Roulstone V; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Kyula J; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Burley A; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Hubbard L; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Pedersen M; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Smith SA; Early Oncology R&D, AstraZeneca, Cambridge, UK., Clancy-Thompson E; Early Oncology R&D, AstraZeneca, Cambridge, UK., Melcher AA; Translational Immunotherapy Team, The Institute of Cancer Research, London, UK., Ono M; Department of Life Sciences, Imperial College London, London, UK., Rullan A; Targeted Therapy Team, The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK., Harrington KJ; Targeted Therapy Team, The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK.

Publikováno v: Nature communications [Nat Commun] 2024 Aug 13; Vol. 15 (1), pp. 6923. Date of Electronic Publication: 2024 Aug 13.

Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21

Autor: Müller, LME, Holmes, M, Michael, JL, Scott, GB, West, EJ, Scott, KJ, Parrish, C, Hall, K, Stäble, S, Jennings, VA, Cullen, M, McConnell, S, Langton, C, Tidswell, EL, Shafren, D, Samson, A, Harrington, KJ, Pandha, H, Ralph, C, Kelly, RJ, Cook, G, Melcher, AA, Errington-Mais, F

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Journal for Immunotherapy of Cancer

Background The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies offer the best chance of disease

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1d00c8a5a850c6ae6bef2b7864420855
http://link.springer.com/article/10.1186/s40425-019-0632-y

Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.

Autor: Samson A; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., West EJ; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., Carmichael J; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., Scott KJ; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., Turnbull S; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., Kuszlewicz B; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., Dave RV; Manchester University NHS Foundation Trust, Manchester, United Kingdom., Peckham-Cooper A; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Tidswell E; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., Kingston J; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Johnpulle M; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., da Silva B; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., Jennings VA; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., Bendjama K; Transgene, Strasbourg, France., Stojkowitz N; Transgene, Strasbourg, France., Lusky M; Transgene, Strasbourg, France., Prasad KR; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Toogood GJ; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Auer R; Ontario Health Research Institute, Ottawa, Canada., Bell J; Ontario Health Research Institute, Ottawa, Canada., Twelves CJ; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., Harrington KJ; The Institute of Cancer Research, London, United Kingdom., Vile RG; Mayo Clinic, Rochester, Minnesota., Pandha H; University of Surrey, Guildford, United Kingdom., Errington-Mais F; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., Ralph C; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., Newton DJ; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., Anthoney A; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom., Melcher AA; The Institute of Cancer Research, London, United Kingdom., Collinson F; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2022 Jun 03; Vol. 10 (6), pp. 745-756.

Oncolytic virus treatment differentially affects the CD56 ^dim and CD56 ^bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity.

Autor: Wantoch M; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Wilson EB; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Droop AP; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Phillips SL; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Coffey M; Oncolytics Biotech Inc, Calgary, Alberta, Canada., El-Sherbiny YM; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Holmes TD; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Melcher AA; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Wetherill LF; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK., Cook GP; Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK.

Publikováno v: Immunology [Immunology] 2022 May; Vol. 166 (1), pp. 104-120. Date of Electronic Publication: 2022 Mar 09.

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.

Autor: Patin EC; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK emmanuel.patin@icr.ac.uk., Dillon MT; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., Nenclares P; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.; Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK., Grove L; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.; Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK., Soliman H; Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK., Leslie I; Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK., Northcote D; Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK., Bozhanova G; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., Crespo-Rodriguez E; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., Baldock H; Biological Services Unit, The Institute of Cancer Research, London, UK., Whittock H; Biological Services Unit, The Institute of Cancer Research, London, UK., Baker G; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., Kyula J; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., Guevara J; Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK., Melcher AA; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., Harper J; Early Oncology R&D, AstraZeneca, Cambridge, UK., Ghadially H; Early Oncology R&D, AstraZeneca, Cambridge, UK., Smith S; Early Oncology R&D, AstraZeneca, Cambridge, UK., Pedersen M; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., McLaughlin M; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., Harrington KJ; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.; Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Mar; Vol. 10 (3).